跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Exon 45
首页
药物
Exon 45
Exon 45
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
EP 3554554 B1
申请人: SAREPTA THERAPEUTICS INC
优先权: 2016
CN
EP
US
WO
11 件公开
Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
US 9926557 B2
申请人: DE KIMPE JOSEPHUS JOHANNES
优先权: 2009
US
8 件公开
Immunosuppression compound and treatment method
US 8501704 B2
申请人: MOURICH DAN V
优先权: 2008
US
6 件公开
US 2007111962 A1
申请人: MOURICH DAN V
优先权: 2006
US
Antisense nucleic acids
US 10144931 B2
申请人: NIPPON SHINYAKU CO LTD
优先权: 2015
CN
EP
US
5 件公开
MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR SKIPPING EXON 45 OF A DMD GENE
EP 4612185 A1
申请人: DYNE THERAPEUTICS INC
优先权: 2022
CN
EP
US
WO
4 件公开
ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 45 SKIPPING
EP 4788816 A2
申请人: AVIDITY BIOSCIENCES INC
优先权: 2023
CN
EP
US
WO
4 件公开
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
EP 4784763 A1
申请人: WAVE LIFE SCIENCES LTD
优先权: 2023
CN
EP
WO
4 件公开
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
US 2002055481 A1
申请人: JAPAN CHEM RES
优先权: 2000
US
2 件公开
Exon skipping oligomers for muscular dystrophy
CN 109311919 A
申请人: SAREPTA THERAPEUTICS INC
优先权: 2016
CN
Generation and correction of a humanized mouse model with a deletion of dystrophin exon 44
US 10687520 B2
申请人: UNIV TEXAS
优先权: 2018
US
第 1 / 2 页
上一页
下一页
药物
反馈